Form 4: Kura Oncology Director Diane L. Parks Acquires 26,000 Stock Options
SEC Form 4 Filing
Diane L. Parks, a director at Kura Oncology, acquired 26,000 stock options on June 5, 2024, exercisable for common stock.
Summary
- On June 5, 2024, Diane L. Parks, a director of Kura Oncology, Inc., acquired 26,000 options to purchase common stock.
- The exercise price of these options is $21.79.
- The options vest in full on the one-year anniversary of the grant date and expire on June 4, 2034.
- Following the transaction, Ms. Parks directly owns 26,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock option grants, which is neutral in sentiment.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
This Form 4 filing is a routine disclosure related to insider transactions, which are common in the biotechnology industry. Monitoring such filings can provide insights into management's sentiment and confidence in the company's prospects.
Stakeholder Impact
- The granting of stock options to a director aligns their interests with those of the shareholders, potentially incentivizing them to work towards increasing shareholder value.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of transaction: Diane L. Parks acquired 26,000 stock options. |
| 06/04/2034 | Expiration date of the stock options. |
| 06/07/2024 | Date of report signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.